References
- Tucker T K, Ritter A J. Naltrexone in the treatment of heroin dependence: a literature review. Drug Alcohol Rev 2000; 19: 73–82
- Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2004; 4
- Comer S D, Sullivan M A, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210–218
- Saunders C. Big future for injectable naltrexone. Aust Doctor 2006, Available at: http://www.australiandoctor.com.au/news/2d/0c03ce2d.asp (accessed 12 October 2007)
- Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev 2005; 24: 411–418
- Comer S, Sullivan M, Yu E, et al. Response to ‘Lack of information in naltrexone study’. Arch Gen Psychiatry 2007; 64: 865
- Hughes J, Cook C. The efficacy of disulfiram: a review of outcome studies. Addiction 1997; 92: 381–395
- Ehret M, Fuller M. Long-acting injectable risperidone. Ann Pharmacother 2004; 38: 2122–2127
- Dinesh M, David A, Quraishi S. Depot pipotiazine palmitate and undecylenate for schizophrenia. Cochrane Database Syst Rev 2004; 4
- Gibson A, Degenhardt L. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007; 26: 405–410
- Caplehorn J RM, Dalton M SYN, Halder F, Petrenas A M, Nisbet J G. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996; 31: 177–196
- Degenhardt L, Hall W, Lynskey M, Warner-Smith M. Illicit drug use. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors, chapter 13, M Ezzati, A D Lopez, A Rodgers, R Murray. World Health Organisation, Geneva 2004; 1109–1176
- Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 2003; 326: 959–960
- Seaman S, Brettle R, Gore S. () Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998; 316: 426–428
- Gibson A, Degenhardt L, Hall W. Opioid deaths can occur in patients with naltrexone implants. Med J Aust 2007; 186: 152–153
- Hulse G K, Tait R J, Comer S D, Sullivan M A, Jacobs I G, Arnold-Reed D. Reducing hospital presentations for opioid overdose in patients treated with sustained release naltrexone implants. Drug Alcohol Depend 2005; 79: 351–357